Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 17.
doi: 10.1002/ejhf.70055. Online ahead of print.

Glucagon-like peptide-1 receptor agonists across the cardiovascular-kidney-metabolic spectrum: One size does not fit all

João Pedro Ferreira  1   2 , Pedro Marques  1 , Bernhard Haring  3   4 , João Sérgio Neves  1
Affiliations
Editorial

Glucagon-like peptide-1 receptor agonists across the cardiovascular-kidney-metabolic spectrum: One size does not fit all

João Pedro Ferreira et al. Eur J Heart Fail. .
No abstract available

PubMed Disclaimer

References

    1. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP‐1 receptor agonists in patients with type 2 diabetes: A systematic review and meta‐analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653–662. https://doi.org/10.1016/s2213‐8587(21)00203‐5
    1. Leite AR, Angélico‐Gonçalves A, Vasques‐Nóvoa F, Borges‐Canha M, Leite‐Moreira A, Neves JS, et al. Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials. Diabetes Obes Metab 2022;24:1676–1680. https://doi.org/10.1111/dom.14707
    1. Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al.; SELECT, FLOW, STEP‐HFpEF, and STEP‐HFpEF DM Trial Committees and Investigators. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP‐HFpEF, and STEP‐HFpEF DM randomised trials. Lancet 2024;404:949–961. https://doi.org/10.1016/S0140‐6736(24)01643‐X
    1. Neves JS, Vasques‐Nóvoa F, Borges‐Canha M, Leite AR, Sharma A, Carvalho D, et al. Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post‐hoc analysis of the FIGHT trial. Diabetes Obes Metab 2023;25:189–197. https://doi.org/10.1111/dom.14862
    1. Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial. Lancet 2024;404:773–786. https://doi.org/10.1016/s0140‐6736(24)01498‐3

Publication types

LinkOut - more resources